Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy
- 31 August 2005
- journal article
- research article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 130 (2) , 321-329
- https://doi.org/10.1016/j.jtcvs.2004.11.041
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemiaThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiationNature Medicine, 2004
- Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarctsNature, 2004
- Gene Transfer of Hepatocyte Growth Factor Attenuates Postinfarction Heart FailureCirculation, 2003
- Endothelial Progenitor CellsCirculation, 2003
- Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic NeovascularizationCirculation, 2003
- Statin Therapy Accelerates ReendothelializationCirculation, 2002
- Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cellsJournal of Clinical Investigation, 2001
- The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral BloodThe Journal of Experimental Medicine, 1997
- Coronary artery bypass grafting in severe left ventricular dysfunction: Excellent survival with improved ejection fraction and functional stateJournal of the American College of Cardiology, 1993